| scholarly article | Q13442814 |
| P50 | author | Rong Tian | Q37839095 |
| John Calvert | Q42718453 | ||
| P2093 | author name string | Saurabh Jha | |
| Arun Ramachandran | |||
| David J Lefer | |||
| Susheel Gundewar | |||
| Sang Yong Ji | |||
| Denise Nunez | |||
| Iris Toedt-Pingel | |||
| Mauricio Anaya-Cisneros | |||
| P2860 | cites work | Metformin: An Update | Q22241145 |
| Role of AMP-activated protein kinase in mechanism of metformin action | Q22241898 | ||
| Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration | Q22241965 | ||
| Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review | Q22242077 | ||
| Metformin | Q22250907 | ||
| Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q22306347 | ||
| AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation | Q24541475 | ||
| PGC-1 coactivators: inducible regulators of energy metabolism in health and disease | Q24541524 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha | Q29620443 | ||
| Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. | Q30359509 | ||
| Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function | Q30480176 | ||
| Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase | Q33965444 | ||
| Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice | Q34961540 | ||
| Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. | Q35213694 | ||
| The AMP-activated protein kinase pathway--new players upstream and downstream. | Q35930365 | ||
| The safety of metformin in heart failure | Q36765255 | ||
| AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury | Q37286204 | ||
| Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis | Q37526796 | ||
| Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals | Q37692490 | ||
| Cytoprotective effects of N,N,N-trimethylsphingosine during ischemia- reperfusion injury are lost in the setting of obesity and diabetes | Q38300037 | ||
| Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study | Q39839307 | ||
| Attenuation of myocardial ischemia-reperfusion injury with nitric oxide replacement therapy | Q40484144 | ||
| Inhibition of N-ethylmaleimide-sensitive factor protects against myocardial ischemia/reperfusion injury | Q42873483 | ||
| Metformin improves cardiac functional recovery after ischemia in rats | Q43978119 | ||
| Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase | Q44453273 | ||
| Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells | Q44468960 | ||
| Mitochondrial abnormalities in myocardium of dogs with chronic heart failure | Q44576578 | ||
| Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction | Q44601934 | ||
| Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus | Q44759159 | ||
| Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling | Q46847423 | ||
| Metformin in heart failure | Q46879293 | ||
| Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase | Q46917092 | ||
| AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. | Q46952844 | ||
| Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle | Q47755014 | ||
| Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy | Q68189721 | ||
| Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts | Q72324128 | ||
| United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd | Q74137575 | ||
| Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease | Q80336398 | ||
| P433 | issue | 3 | |
| P921 | main subject | metformin | Q19484 |
| heart failure | Q181754 | ||
| P304 | page(s) | 403-411 | |
| P577 | publication date | 2008-12-18 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure | |
| P478 | volume | 104 |
| Q35771294 | 5'-AMP Activated Protein Kinase is Involved in the Regulation of Myocardial β-Oxidative Capacity in Mice |
| Q92167256 | A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes |
| Q41498937 | A systematic review and meta-analysis of the protective effects of metformin in experimental myocardial infarction |
| Q40792299 | AICAR administration affects glucose metabolism by upregulating the novel glucose transporter, GLUT8, in equine skeletal muscle. |
| Q35238018 | AMP activated protein kinase-α2 regulates expression of estrogen-related receptor-α, a metabolic transcription factor related to heart failure development |
| Q33455297 | AMP-activated protein kinase confers protection against TNF-{alpha}-induced cardiac cell death |
| Q42154599 | AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction |
| Q38024322 | AMP-activated protein kinase in the control of cardiac metabolism and remodeling |
| Q38039283 | AMP-activated protein kinase regulation and biological actions in the heart |
| Q38026549 | AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases |
| Q42553494 | AMP-dependent protein kinase activators: not just for diabetes? |
| Q90321049 | AMPK blunts chronic heart failure by inhibiting autophagy |
| Q36048973 | AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism |
| Q38998410 | AMPK in Cardiovascular Diseases |
| Q38698086 | AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation. |
| Q64251759 | AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases |
| Q35892560 | AMPK isoform expression in the normal and failing hearts |
| Q33832521 | Activation of AMP-activated protein kinase alpha1 alleviates endothelial cell apoptosis by increasing the expression of anti-apoptotic proteins Bcl-2 and survivin |
| Q54383877 | Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: interference of AMPK/PGC-1α pathway. |
| Q47914394 | Activation of γ2-AMPK Suppresses Ribosome Biogenesis and Protects Against Myocardial Ischemia/Reperfusion Injury. |
| Q24606408 | Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice |
| Q86109966 | Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats |
| Q24646027 | Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing |
| Q26740006 | An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus |
| Q50872186 | Angiotensin II type 2 receptor (AT2R) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion. |
| Q38998435 | Animal Models to Study AMPK. |
| Q37187900 | Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status |
| Q64241996 | Autoantibodies Against β-Adrenoceptor Exaggerated Ventricular Remodeling by Inhibiting CTRP9 Expression |
| Q38672214 | Autophagy during cardiac remodeling |
| Q26866165 | Autophagy in cardiovascular biology |
| Q89617548 | Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors |
| Q37999635 | Autophagy, myocardial protection, and the metabolic syndrome. |
| Q38422854 | Berberine attenuates ischemia-reperfusion injury via regulation of adenosine-5'-monophosphate kinase activity in both non-ischemic and ischemic areas of the rat heart |
| Q38101620 | Biological activities of guanidine compounds, 2008 - 2012 update |
| Q100523694 | Biphasic effect of metformin on human cardiac energetics |
| Q35063002 | Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms |
| Q30426853 | Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies |
| Q35661775 | Cardiac Fibrosis Alleviated by Exercise Training Is AMPK-Dependent |
| Q35204828 | Cardiac NO signalling in the metabolic syndrome |
| Q37495811 | Cardiac metabolism in heart failure: implications beyond ATP production. |
| Q56991273 | Cardiotoxicity with vascular endothelial growth factor inhibitor therapy |
| Q27013561 | Cellular and molecular mechanisms of metformin: an overview |
| Q42516922 | Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. |
| Q47196867 | Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction |
| Q92604578 | Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non-obese type 2 diabetic Goto-Kakizaki rats |
| Q33921334 | Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats |
| Q33769656 | Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II |
| Q27003819 | Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement |
| Q37694958 | Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria |
| Q28395852 | Diabetic cardiomyopathy: signaling defects and therapeutic approaches |
| Q55282643 | Does chronic metformin therapy offer cardiomyoprotection in coronary artery bypass grafting surgery patients? A case-control study. |
| Q41221005 | Does long-term metformin treatment increase cardiac lipoprotein lipase? |
| Q53063989 | Early diabetes treatment does not prevent sympathetic dysinnervation in the streptozotocin diabetic rat heart. |
| Q38855358 | Effect of AMP-activated protein kinase activation on cardiac fibroblast proliferation induced by coxsackievirus B3. |
| Q57820978 | Effect of Intracoronary Metformin on Myocardial Infarct Size in Swine |
| Q54616760 | Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats. |
| Q34042151 | Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion |
| Q36978797 | Enhancement of Glucose Metabolism via PGC-1α Participates in the Cardioprotection of Chronic Intermittent Hypobaric Hypoxia |
| Q41855554 | Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury |
| Q39486441 | Epinephrine-induced MMP expression is different between skeletal fibroblasts and myoblasts |
| Q49923296 | Establishment of a PRKAG2 cardiac syndrome disease model and mechanism study using human induced pluripotent stem cells |
| Q51655884 | Exacerbated cardiac fibrosis induced by β-adrenergic activation in old mice due to decreased AMPK activity. |
| Q34236772 | Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase |
| Q38842771 | From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. |
| Q30497008 | Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice |
| Q30417331 | Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart |
| Q27005955 | Heart failure and mitochondrial dysfunction: the role of mitochondrial fission/fusion abnormalities and new therapeutic strategies |
| Q51316426 | Hypoglycemic effect of catalpol on high-fat diet/streptozotocin-induced diabetic mice by increasing skeletal muscle mitochondrial biogenesis. |
| Q40630534 | Impact of caloric restriction on myocardial ischaemia/reperfusion injury and new therapeutic options to mimic its effects |
| Q35155185 | Impact of metformin on endothelial ischemia-reperfusion injury in humans in vivo: a prospective randomized open, blinded-endpoint study |
| Q38317335 | Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1α signaling contributing to increased vulnerability in diabetic heart |
| Q35967093 | Inhibition of miR-15 protects against cardiac ischemic injury |
| Q90308558 | Integrative analysis of competing endogenous RNA networks reveals the functional lncRNAs in heart failure |
| Q87430047 | It takes more than one CAMERA to study cardiovascular protection by metformin |
| Q35221451 | LKB1/Mo25/STRAD uniquely impacts sarcomeric contractile function and posttranslational modification |
| Q41878667 | Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway |
| Q59138235 | Metabolic Effects of Metformin in the Failing Heart |
| Q43169008 | Metabolic therapy in cardiac surgery--"Optimizing the engine's fuel supply and more...". |
| Q90567795 | Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection |
| Q41864380 | Metformin Inhibits Isoproterenol-induced Cardiac Hypertrophy in Mice |
| Q59128194 | Metformin Modulates High Glucose-Incubated Human Umbilical Vein Endothelial Cells Proliferation and Apoptosis Through AMPK/CREB/BDNF Pathway |
| Q57192333 | Metformin Protects against HO-Induced Cardiomyocyte Injury by Inhibiting the miR-1a-3p/GRP94 Pathway |
| Q64095068 | Metformin Protects the Heart Against Hypertrophic and Apoptotic Remodeling After Myocardial Infarction |
| Q58723952 | Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study |
| Q51310417 | Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study. |
| Q45070301 | Metformin attenuates ER stress-induced mitochondrial dysfunction |
| Q43143850 | Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway |
| Q41444311 | Metformin attenuates myocardial ischemia-reperfusion injury via up-regulation of antioxidant enzymes. |
| Q37729486 | Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. |
| Q35114963 | Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis |
| Q41893725 | Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia |
| Q51373277 | Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. |
| Q37209499 | Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study |
| Q37018236 | Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK/eNOS pathway in diabetic mice |
| Q37508043 | Metformin in Diabetic Patients with Heart Failure: Safe and Effective? |
| Q36297833 | Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial |
| Q35740361 | Metformin increases degradation of phospholamban via autophagy in cardiomyocytes |
| Q38682430 | Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study |
| Q90157493 | Metformin preconditioning improves hepatobiliary function and reduces injury in a rat model of normothermic machine perfusion and orthotopic transplantation |
| Q47297378 | Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs |
| Q41885618 | Metformin prevents the development of chronic heart failure in the SHHF rat model. |
| Q37611026 | Metformin promotes the survival of transplanted cardiosphere-derived cells thereby enhancing their therapeutic effect against myocardial infarction |
| Q33757711 | Metformin protects against infection-induced myocardial dysfunction |
| Q96017824 | Metformin protects against ischaemic myocardial injury by alleviating autophagy-ROS-NLRP3-mediated inflammatory response in macrophages |
| Q33632353 | Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase α2. |
| Q28541996 | Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study |
| Q64058371 | Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-α/VLCAD pathway |
| Q42153380 | Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats |
| Q98464593 | Metformin suppresses inflammation and apoptosis of myocardiocytes by inhibiting autophagy in a model of ischemia-reperfusion injury |
| Q33793434 | Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes |
| Q38083008 | Metformin therapy in diabetes: the role of cardioprotection |
| Q42908257 | Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study |
| Q91797819 | Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study |
| Q34614524 | Metformin use and mortality in ambulatory patients with diabetes and heart failure |
| Q36436404 | Metformin: Midlife maturity, maiden charm |
| Q27011752 | Mitochondria and cardiovascular aging |
| Q27005632 | Mitochondria as a therapeutic target in heart failure |
| Q37246892 | Mitochondria in cardiac hypertrophy and heart failure |
| Q92267248 | Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction |
| Q26851293 | Mitochondrial dysfunction in heart failure |
| Q89397986 | Mitochondrial function in the heart: the insight into mechanisms and therapeutic potentials |
| Q46432453 | Mitochondrial redox plays a critical role in the paradoxical effects of NAPDH oxidase-derived ROS on coronary endothelium. |
| Q27006868 | Molecular basis of physiological heart growth: fundamental concepts and new players |
| Q36042624 | Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. |
| Q36627621 | NecroX-5 protects mitochondrial oxidative phosphorylation capacity and preserves PGC1α expression levels during hypoxia/reoxygenation injury |
| Q27023545 | New promises for metformin: advances in the understanding of its mechanisms of action |
| Q38374396 | Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease |
| Q64376957 | N‑terminal truncated peroxisome proliferator‑activated receptor‑γ coactivator‑1α alleviates phenylephrine‑induced mitochondrial dysfunction and decreases lipid droplet accumulation in neonatal rat cardiomyocytes |
| Q51087878 | Obesity-associated cardiac pathogenesis in broiler breeder hens: Pathological adaption of cardiac hypertrophy. |
| Q92217698 | Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics |
| Q54110304 | Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCα/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction. |
| Q36712777 | Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats |
| Q33686430 | Potential biomarker of metformin action |
| Q35205624 | Preservation of cellular glutathione status and mitochondrial membrane potential by N-acetylcysteine and insulin sensitizers prevent carbonyl stress-induced human brain endothelial cell apoptosis |
| Q53052642 | Reduced scar maturation and contractility lead to exaggerated left ventricular dilation after myocardial infarction in mice lacking AMPKα1. |
| Q36206138 | Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms |
| Q37366972 | Renoprotective Effects of Metformin are Independent of Organic Cation Transporters 1 &2 and AMP-activated Protein Kinase in the Kidney |
| Q26749206 | Rescue of Heart Failure by Mitochondrial Recovery |
| Q26742059 | Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity |
| Q28553008 | Resveratrol Reverses Functional Chagas Heart Disease in Mice |
| Q47122036 | Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism. |
| Q57488674 | Risk of regorafenib-induced cardiovascular events in patients with solid tumors: A systematic review and meta-analysis |
| Q37476530 | Role of mitochondrial dysfunction and altered autophagy in cardiovascular aging and disease: from mechanisms to therapeutics. |
| Q47744644 | SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy. |
| Q36614556 | SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction |
| Q39199277 | Simulated microgravity increases myocardial susceptibility to ischemia-reperfusion injury via a deficiency of AMP-activated protein kinase |
| Q35612438 | Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin |
| Q37819301 | Targeting AMPK for cardiac protection: opportunities and challenges |
| Q27694733 | Targeting myocardial substrate metabolism in heart failure: potential for new therapies |
| Q38999231 | Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy? |
| Q34587748 | The PGC-1 cascade as a therapeutic target for heart failure |
| Q89604720 | The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity |
| Q35275451 | The beneficial effects of AMP kinase activation against oxidative stress are associated with prevention of PPARα-cyclophilin D interaction in cardiomyocytes |
| Q38022224 | The effect of metformin on insulin resistance and exercise parameters in patients with heart failure |
| Q38062033 | The impact of current and novel anti-diabetic therapies on cardiovascular risk |
| Q88013533 | The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies |
| Q26829731 | The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise |
| Q37926558 | The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury |
| Q36097027 | The role of PPARα in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia/reperfusion in rats |
| Q50796094 | Transcript variant dictates Prkag2 cardiomyopathy? |
| Q37592833 | Treating percutaneous coronary intervention-related myocardial injury with metformin |
| Q37297198 | Treatment strategies for the prevention of heart failure |
| Q42324391 | Two-step activation of FOXO3 by AMPK generates a coherent feed-forward loop determining excitotoxic cell fate |
| Q38373147 | Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT. |
| Q93178799 | Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction |
| Q58732794 | Yiqihuoxue decoction protects against post-myocardial infarction injury via activation of cardiomyocytes PGC-1α expression |
Search more.